Stock Fundamentals

Reality check: Sun Pharma: Losing potency

Dhuraivel Gunasekaran | Updated on December 09, 2018 Published on December 09, 2018

The stock of Sun Pharma fell more than 16 per cent last week following allegations by a brokerage firm and a whistle-blower complaint to SEBI. Reports that SEBI may reopen the investigation into the insider trading case against the company and its promoters — settled through the consent mechanism last year — spooked investors. In a conference call to clarify matters, the management addressed the allegations, including on insider trading in the Ranbaxy deal, related party transactions and a spike in loans and advances in FY18.

The stock price has corrected 16 per cent and the stock trades at a discount to peers such as Dr Reddy’s, Lupin and Cipla. Sun Pharma’s earnings have been on a revival path and the outlook is robust, especially on the speciality business. The company also appears to have overcome regulatory hurdles, especially in the US.

But much would depend on how SEBI acts on the allegations. This would be a major hurdle for the stock .

Read further by subscribing to

The Hindu Businessline

What You'll Get

  • Web + Mobile

    Access exclusive content of the Hindu Businessline across desktops, tablet and mobile device.

  • Exclusive portfolio stories and investment advice

    Gain exclusive market insights from the Hindu Businessline's research desk.

  • Ad free experience

    Experience cleaner site with zero ads and faster load times.

  • Personalised dashboard

    Customize your preference and get a personalized recommendation of stories based on your intrest.

This article is closed for comments.
Please Email the Editor